Last Updated: November 8, 2026

CLINICAL TRIALS PROFILE FOR OCTREOTIDE ACETATE

« Back to Dashboard

All Clinical Trials for OCTREOTIDE ACETATE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002779 ↗	Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1998-02-01	RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin's lymphoma.
NCT00002779 ↗	Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	Completed	Alliance for Clinical Trials in Oncology	Phase 2	1998-02-01	RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin's lymphoma.
NCT00002864 ↗	Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer	Completed	NCIC Clinical Trials Group	Phase 3	1996-09-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of estrogen. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without octreotide in treating postmenopausal women who have stage I, stage II, or stage III breast cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for OCTREOTIDE ACETATE

Condition Name

Chart
Table

Condition Name for OCTREOTIDE ACETATE
Intervention	Trials
Acromegaly	12
Diarrhea	5
Colorectal Cancer	5
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for OCTREOTIDE ACETATE
Intervention	Trials
Acromegaly	12
Neuroendocrine Tumors	10
Carcinoid Tumor	8
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for OCTREOTIDE ACETATE

Trials by Country

Map
Table

Trials by Country for OCTREOTIDE ACETATE
Location	Trials
United States	219
Canada	14
Italy	4
Hungary	3
Belarus	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for OCTREOTIDE ACETATE
Location	Trials
New York	10
Ohio	9
Minnesota	9
Illinois	9
California	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for OCTREOTIDE ACETATE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for OCTREOTIDE ACETATE
Clinical Trial Phase	Trials
PHASE1	2
Phase 4	3
Phase 3	16
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for OCTREOTIDE ACETATE
Clinical Trial Phase	Trials
Completed	28
Terminated	8
Not yet recruiting	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OCTREOTIDE ACETATE

Sponsor Name

Chart
Table

Sponsor Name for OCTREOTIDE ACETATE
Sponsor	Trials
National Cancer Institute (NCI)	17
Novartis Pharmaceuticals	7
Novartis	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for OCTREOTIDE ACETATE
Sponsor	Trials
Other	29
Industry	24
NIH	19
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.